A Chatbot to Support Substance Use Recovery

NCT ID: NCT06845878

Last Updated: 2025-03-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-07

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if/how an AI chatbot can support patients who in recovery for substance use, specifically those who are receiving medication for opioid use disorder.

Can the chatbot help lower drug use? Can the chatbot help improve clinical appointment adherence? Can the chatbot help patients build self-efficacy in leading their own recovery journey? Will the chatbot help reduce workload burden for primary care teams? Can the chatbot serve as a safe, useful and engaging tool to support patients?

Researchers will investigate the effects of using a chatbot to support follow-up care for patients in opioid use recovery.

Participants will:

* Receive access to a chatbot for 12 weeks that they can use to prepare for upcoming clinical appointments, find community resources, learn about urge-surfing and wellness techniques, and query for assistance with other recovery-related information and tasks
* Complete surveys and provide user feedback

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opiate-Related Disorders Opiate Substitution Treatment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Pre-Post Intervention
Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chatbot

Participants will receive access to a chatbot for 12 weeks that can be used from a mobile device to support follow-up care and recovery needs.

Group Type EXPERIMENTAL

chatbot

Intervention Type OTHER

Participants will:

* Participate in a baseline session to complete an initial survey and get trained on using the chatbot
* Use the chatbot for 12 weeks and submit a brief weekly survey to provide feedback
* Complete a final survey to provide substance use and health information as well as give feedback on the experience using the chatbot
* Allow access to a limited set of demographic, substance use and health information in electronic health record for study analyses and context.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

chatbot

Participants will:

* Participate in a baseline session to complete an initial survey and get trained on using the chatbot
* Use the chatbot for 12 weeks and submit a brief weekly survey to provide feedback
* Complete a final survey to provide substance use and health information as well as give feedback on the experience using the chatbot
* Allow access to a limited set of demographic, substance use and health information in electronic health record for study analyses and context.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Suzy conversational agent

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-65 years old
* Comfortable with reading, understanding, and communicating in English
* Receiving medication treatment for OUD at MGH?
* Able to participate in a remote interview?
* Own or have reliable access to Wi-Fi or a cellular network
* Willing to use a mobile device to access the chatbot?

Exclusion Criteria

* Has any cognitive, visual, or auditory impairments that may prevent the participant from using the chatbot on a mobile device?
* Unstable medical condition that compromises the ability to safely participate
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role collaborator

University of California, Los Angeles

OTHER

Sponsor Role collaborator

Massachusetts General Hospital

OTHER

Sponsor Role collaborator

Dimagi Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Y. Xian Ho, PhD

Role: PRINCIPAL_INVESTIGATOR

Dimagi Inc.

Jonathan Jackson, MEng

Role: PRINCIPAL_INVESTIGATOR

Dimagi Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dimagi Study Team

Role: CONTACT

617-649-2214

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Cecely Sterling-Maisel, BA

Role: primary

617-643-9977

Joanna Streck, PhD

Role: backup

617-726-2000

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2R44DA050218-02

Identifier Type: NIH

Identifier Source: secondary_id

View Link

2R44DA050218

Identifier Type: NIH

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Digitally Assisted Recovery Coach
NCT05393544 COMPLETED NA
Early Re-Intervention Experiment 2
NCT01153594 COMPLETED PHASE3
Monitoring and Feedback in Substance Abuse Treatment
NCT01465490 COMPLETED PHASE1/PHASE2
The Total Health Study
NCT01415206 COMPLETED NA